Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Piergiorgio Chiodini is active.

Publication


Featured researches published by Piergiorgio Chiodini.


Psychoneuroendocrinology | 1992

The brain as a target for adrenocortical steroids: Cognitive implications

Emilia Martignoni; Alfredo Costa; Elena Sinforiani; Antonio Liuzzi; Piergiorgio Chiodini; Marco Mauri; Giorgio Bono; Giuseppe Nappi

It is well established that a reciprocal control exists between the brain and glucocorticoid hormones. The brain regulates adrenocortical function via hypothalamic corticotrophin releasing hormone-41 (CRH-41), glucocorticoids act at specific receptors in the hippocampus, thus promoting negative feedback mechanisms. Because the hippocampus is a major site for memory processes, a role for excessive/long-lasting plasma glucocorticoid levels has been suggested in conditions of mental impairment. Major depression, Cushings disease, and dementia of the Alzheimer type are disorders which share hyperactivity of the hypothalamo-pituitary-adrenal axis, as well as symptoms of cognitive decline. Although the mechanisms leading to hypercortisolemia appear to be different in each case, the neuropsychological features of these three disorders accord with the hypothesis of glucocorticoid-associated brain damage. It therefore is important to find pharmacological strategies that will avert or reduce these potential consequences on brain function.


The New England Journal of Medicine | 1985

Low Doses of Dopamine Agonists in the Long-Term Treatment of Macroprolactinomas

Antonio Liuzzi; Daniela Dallabonzana; Giuseppe Oppizzi; Giuseppe Verde; Renato Cozzi; Piergiorgio Chiodini; Giovanni Luccarelli

To evaluate the long-term effects of dopamine agonists in the treatment of macroprolactinoma, we studied prolactin levels and tumor size for 30 to 88 months (57 +/- 14, mean +/- S.D.) in 38 patients treated with bromocriptine or lisuride. Elevated prolactin levels became normal in 30 patients, and the tumor shrank in 29. After two years of treatment, we attempted to reduce the maintenance dose (5 to 20 mg of bromocriptine per day or 0.4 to 0.8 mg of lisuride per day); in 21 patients no changes in prolactin levels or tumor size were observed over 6 to 52 months with 0.625 to 10 mg of bromocriptine per day or 0.05 mg of lisuride per day. However, it was possible to withdraw the drug in only one patient. We conclude that dopamine agonists are usually effective treatments for macroprolactinoma and that after a response has been obtained, it can be maintained in many patients with a greatly reduced dose.


The Journal of Clinical Endocrinology and Metabolism | 1974

DECREASED PLASMA GROWTH HORMONE (GH) LEVELS IN ACROMEGALICS FOLLOWING CB 154(2-Br-α-ERGOCRYPTINE) ADMINISTRATION1

A. Liuzzi; Piergiorgio Chiodini; L. Botalla; G. Cremascoli; E. E. Müller; F. Silvestrini


The Journal of Clinical Endocrinology and Metabolism | 1981

Size reduction of macroprolactinomas by bromocriptine or lisuride treatment.

Piergiorgio Chiodini; Antonio Liuzzi; Renato Cozzi; Giuseppe Verdexs; Giuseppe Oppizzi; Daniela Dallabonzana; Barbara Spelta; F. Silvestrini; Giampaola Borghi; Giuseppe Luccarelli; Ernst Rainer; Reinhardt Horowski


The Journal of Clinical Endocrinology and Metabolism | 1972

INHIBITORY EFFECT OF L-DOPA ON GH RELEASE IN ACROMEGALIC PATIENTS1

A. Liuzzi; Piergiorgio Chiodini; L. Botalla; G. Cremascoli; F. Silvestrini


The Journal of Clinical Endocrinology and Metabolism | 1974

Growth Hormone (GH)-Releasing Activity of TRH and GH-Lowering Effect of Dopaminergic Drugs in Acromegaly: Homogeneity in the Two Responses

A. Liuzzi; Piergiorgio Chiodini; L. Botalla; F. Silvestrini; E. E. Müller


The Journal of Clinical Endocrinology and Metabolism | 1974

Inhibitory Effect of Dopaminergic Stimulation on GH Release in Acromegaly

Piergiorgio Chiodini; A. Liuzzi; L. Botalla; G. Cremascoli; F. Silvestrini


The Journal of Clinical Endocrinology and Metabolism | 1976

Inhibitory Effect of an Ergoline Derivative, Methergoline, on Growth Hormone and Prolactin Levels in Acromegalic Patients

Piergiorgio Chiodini; A. Liuzzi; E. E. Muller; L. Botalla; G. Cremascoli; Giuseppe Oppizzi; Giuseppe Verde; F. Silvestrini


The Journal of Clinical Endocrinology and Metabolism | 1986

Relationship between Somatomedin-C and Growtyh Hormone Levels in Acromegaly: Basal and Dynamic Evaluation

Giuseppe Oppizzi; M. M. Petroncini; Daniela Dallabonzana; Renato Cozzi; Giuseppe Verde; Piergiorgio Chiodini; A. Liuzzi


The Journal of Clinical Endocrinology and Metabolism | 1984

Dopaminergic Treatment of Acromegaly: Different Effects on Hormone Secretion and Tumor Size *

Giuseppe Oppozzi; Antonio Liuzzi; Piergiorgio Chiodini; Dallabonzana Daniela; Barbara Spelta; F. Silvestrini; Gimpaolo Borghi; Cristina Tonon

Collaboration


Dive into the Piergiorgio Chiodini's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Giuseppe Oppizzi

Casa Sollievo della Sofferenza

View shared research outputs
Top Co-Authors

Avatar

A. Liuzzi

Casa Sollievo della Sofferenza

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge